SOPHiA Genetics (SOPH) Q1 2026 Earnings Transcript

SOPHiA Genetics reported Q1 revenue of $21.7 million, up 22% year over year, with platform analysis volume rising 16% to 108,000 and net dollar retention improving to 117%. The company reaffirmed full-year 2026 revenue guidance of $92 million to $94 million and adjusted EBITDA loss guidance of $29 million to $32 million, while gross margin held strong at 75.4% adjusted despite FX headwinds and $700,000 of net litigation impact. Management highlighted accelerating U.S. adoption, stronger biopharma momentum, and improving customer onboarding as key growth drivers.

Analysis

The key read-through is that SOPH is shifting from a pure top-line adoption story to a genuine operating leverage story, but the market should not extrapolate linear margin expansion. The combination of stronger net retention, higher-ASP application mix, and modest cost actions creates a second-order effect: incremental revenue in the second half should drop through at a meaningfully better rate than last year, especially if onboarding latency compresses further. That makes the next two quarters more important than the headline guidance range, because execution on customer go-lives will likely determine whether the company can beat the low end or merely land inside it.

Competitive dynamics are improving for SOPH against both decentralized testing peers and centralized reference labs. Regional density in the U.S. can become self-reinforcing once a few anchor institutions standardize on the platform, because it raises switching costs for adjacent hospitals and increases the value of the clinical network to pharma partners. That said, the real strategic winner may be the biopharma stack: if SOPH can convert diagnostics usage into recurring CDx and real-world evidence workflows, it creates a monetization layer that competitors with narrower clinical footprints will struggle to replicate.

The main bear case is not demand, but translation and timing. FX headwinds can mask underlying improvement for several quarters, and the Latin America weakness shows that SOPH is still vulnerable to geography-specific execution issues that can offset gains elsewhere. Litigation is also less about the current dollar amount than the risk of management distraction and delayed product commercialization in higher-value applications. The stock likely works if investors gain confidence that H2 onboarding and pharma ramp are both real; if either slips, the market will quickly compress the multiple back to a simple revenue-growth name.

Consensus appears to be underestimating how much of this year’s upside is coming from mix, not volume. If liquid biopsy and enhanced exomes continue to expand as a share of tests, gross margin and revenue per analysis can rise together, which is unusual for an early-stage platform business and materially improves the path to breakeven. The opportunity is therefore not just a recovery in growth, but a potential rerating toward software-like unit economics if the company proves repeatability in the U.S. and in pharma.

Key Decisions for Investors

• Long SOPH for 3-6 months on pullbacks, targeting a rerating if H2 onboarding converts; risk/reward is attractive if revenue beats the low end of guidance and adjusted EBITDA trend tightens faster than expected.
• Pair trade: long SOPH / short GH over 1-2 quarters to express platform share gain and litigation asymmetry; SOPH has multiple expansion potential while GH faces continued legal and competitive pressure.
• Buy SOPH call spreads into any post-earnings volatility if the stock sells off on FX noise; the cleaner catalyst is confirmation of go-live timing and pharma contribution in the next two quarters.
• Avoid chasing after sharp upside days until management proves the back-half ramp; the key risk is onboarding slippage, which would hit sentiment faster than it would hit fundamentals.
• Watch AZN and JNJ as indirect beneficiaries of SOPH’s CDx traction; if SOPH executes, those partners gain a lower-friction commercialization channel, but the cleaner trade remains SOPH equity rather than chasing the pharma read-through.